Welcome to our dedicated page for Unicycive Therapeutics SEC filings (Ticker: UNCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Unicycive Therapeutics filings document the regulatory, financing, governance, and operating disclosures of a Nasdaq-listed clinical-stage biotechnology company focused on kidney disease therapies. Form 8-K reports furnish financial results and business updates, including disclosures related to oxylanthanum carbonate, NDA activity, manufacturing matters, and the company’s cash and capital resources.
The filing record also covers common stock registered on the Nasdaq Capital Market, emerging growth company status, at-the-market equity sales under a shelf registration statement, and board and executive-governance matters. Proxy materials document director elections, auditor ratification, stockholder voting mechanics, and annual meeting procedures, while other current reports address securities litigation risk tied to public statements about the OLC program.
Unicycive Therapeutics filed its Q3 2025 10-Q, showing larger resources and continued R&D investment. Cash and cash equivalents were $42.7 million as of September 30, 2025, up from $26.1 million at year-end 2024, reflecting equity activity. Total assets were $50.6 million and stockholders’ equity was $37.5 million.
The company reported a Q3 2025 net loss of $6.0 million and a nine‑month net loss of $11.9 million. Operating expenses were $7.3 million in Q3 (R&D $3.0 million; G&A $4.4 million). Other income benefited from a $1.1 million non‑cash gain from the change in fair value of warrant liabilities in Q3, and $9.8 million for the nine months.
Operating cash outflows were $23.3 million for the nine months. To fund operations, Unicycive sold 8,046,736 shares via its sales agreement with Guggenheim at an average price of $4.94, paying $1.2 million in commissions and receiving approximately $38.6 million in net proceeds. A 1‑for‑10 reverse stock split became effective in June 2025. 20,850,363 shares were outstanding as of September 30, 2025, and 21,491,396 as of November 12, 2025.
Unicycive Therapeutics (UNCY) furnished an 8-K with preliminary cash data and a regulatory update. The company expects to report approximately $42 million in cash and cash equivalents as of September 30, 2025, based on preliminary, unaudited figures. The company’s independent registered public accounting firm has not reviewed these figures, and complete quarterly results will appear in the upcoming Form 10-Q for the quarter ended September 30, 2025.
Unicycive also furnished a press release announcing an update from its meeting with the U.S. Food and Drug Administration and the timing of the resubmission of its New Drug Application for Oxylanthanum Carbonate, following a Complete Response Letter dated June 30, 2025.
Unicycive Therapeutics director Gaurav Aggarwal reported a Form 4 disclosing a non-derivative purchase of 652,900 shares of common stock on 08/25/2025. Following the transaction, the report shows beneficial ownership of 1,789,915 shares attributed indirectly through Vivo Opportunity Fund Holdings L.P., of which the reporting person is a managing member. The filing also reports a disposition of 3,199.21 shares of Series A-2 Prime Preferred Stock (issued March 14, 2024) and explains each preferred share converts using an original per-share price of $1,000 divided by $4.90, subject to blocking provisions. The reporting person disclaims beneficial ownership except for pecuniary interest.
Unicycive Therapeutics, Inc. disclosed that, after June 30, 2025, it sold 3,549,846 shares of common stock under a sales agreement with Guggenheim Securities, LLC. The shares were sold at an average price of $4.56 per share, generating net proceeds of approximately $16.3 million for the company.
This at-the-market style equity financing increases Unicycive’s cash resources but also adds new shares to its common stock base. The filing does not detail specific uses for the funds, only that the proceeds were received by the company.
Great Point Partners, LLC and two associated individuals filed a Schedule 13G/A reporting joint beneficial ownership of 796,558 shares of Unicycive Therapeutics, Inc. common stock, representing 6.24% of the 12,768,239 shares outstanding cited from the issuer's June 20, 2025 filing. The filing shows shared voting and dispositive power over those shares and no sole voting or dispositive power. The record holders are Biomedical Value Fund, L.P. (510,494 shares) and Biomedical Offshore Value Fund, Ltd. (286,064 shares); Great Point is investment manager of both and disclaims beneficial ownership except to the extent of pecuniary interests. The Reporting Persons executed a Joint Filing Agreement dated August 14, 2025, and certified the holdings were not acquired to change or influence control.
Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, report beneficial ownership of 1,234,596 shares of Unicycive Therapeutics, Inc. (CUSIP 90466Y103), representing 9.99% of the outstanding common stock as of June 30, 2025. The reported total includes 295,394 shares that may be acquired within 60 days upon exercise of warrants. Nantahala is identified as an investment adviser and Messrs. Harkey and Mack file as control persons in respect of shares held by funds and managed accounts under Nantahala's control. Blackwell Partners LLC - Series A, a fund advised by Nantahala, has rights to dividends or sale proceeds for more than 5% of the shares reported.
Biotechnology Value Fund and affiliated entities reported beneficial ownership positions in Unicycive Therapeutics (UNCY) as of June 30, 2025. The filing discloses adjusted holdings after a one-for-ten reverse stock split and extensive warrant positions that convert into Series A preferred stock and then into common shares subject to a 9.99% beneficial ownership limitation. Individual reported holdings: BVF 777,308 shares (~5.7%), BVF II 591,650 shares (~4.4%), Trading Fund OS 35,480 shares (<1%), and affiliated entities collectively up to 1,417,117 shares (~9.99%). The statement explains which warrant tranches (A, B, C) are exercisable, exercise-price relationships and that the Beneficial Ownership Limitation restricts conversion of some tranches (notably Tranche C).
Unicycive Therapeutics reported that it has issued a press release announcing its financial results for the three months ended June 30, 2025 and provided a business update. The company furnished that press release as Exhibit 99.1 to its Form 8-K and clarified the disclosure is being furnished, not filed for purposes of the Exchange Act and will not be incorporated by reference into registration statements, except as expressly stated. The Form 8-K also identifies the company as an emerging growth company.
Unicycive Therapeutics (UNCY) reported interim financial results for the quarter ended June 30, 2025 showing $22.3 million in cash and total assets of $30.0 million, down slightly from $31.7 million at year-end. Total liabilities fell materially to $13.6 million from $24.2 million, driven largely by a decline in the warrant liability from $18.9 million to $10.2 million, which reduced reported expense volatility.
The company recorded a six-month net loss of $5.9 million, an improvement from a $11.1 million loss in the prior-year period, as operating expenses decreased to $15.0 million from $16.6 million. Cash used in operating activities was $17.3 million for the six months, and net cash provided by financing activities was $13.5 million, including $12.6 million from a secondary offering. Management states it believes it has sufficient resources for at least one year under current plans. The filing also discloses a 1-for-10 reverse stock split effective June 20, 2025 and ongoing reliance on future financing to complete development and commercial efforts.